The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...

Men with PAH had a larger right heart size and worse survival than women, independent of body size and functional status, a ...

Professor Christopher Denton discusses key aspects of the 2024 British Society for Rheumatology guideline on managing ...

A new molecular imaging technique-18F-FAPI PET-can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker ...

Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD ... We explored treatment regimens (mono ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said ...

The 2023 ESH guidelines recommend initiation ... individuals with both grade 1 hypertension and a low risk of cardiovascular disease. 2 By contrast, the 2017 American and 2024 ESC guidelines recommend ...

Background: Pulmonary arterial hypertension (PAH) poses a significant health challenge ... Other PH subgroups (group 2–5) were not included because of their different pathophysiology, treatment, and ...

A groundbreaking development in hypertension treatment has emerged from the University of South Wales, offering new hope for the 1.28 billion adults worldwide affected by high blood pressure.

A speaker highlighted key advances in the treatment of hypertension in 2024. Topics included insights on the timing of blood pressure medication; impact of bariatric surgery vs. medical therapy on ...